BeiGene
Business Services · Massachusetts, United States · 10,000 Employees
View Company Info for Free
About
Headquarters
55 Cambridge Pkwy Ste 700W, Cambridge, Massachu...Phone Number
(781) 801-1800Website
www.beigene.comRevenue
$3.1 BillionStock Symbol
BGNEIndustry
Most Recent Scoops
Highlights
$4.8B
Total Funding Amount
$1B
Most Recent Funding Amount
7
Number of Funding Rounds
Who is BeiGene
BeiGene Org Chart
Is BeiGene your ideal customer?
Let us give you the heads up on whether it's a good time to reach out
BeiGene, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at BeiGene
Funding: Get notified immidiatlly once BeiGene has new funding data
Check out if BeiGene is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check if BeiGene has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on BeiGene recently announced quarterly report
Website visits: Recent activity has been detected on your website
Click to see if BeiGene had a recent Job posting/layoffs
Product Launch: Get notified when BeiGene launches new products
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find 2 more new buyers
Compare Similar Companies to BeiGene
Compare insights from companies similar to BeiGene, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
BeiGene Email Formats
BeiGene uses at least 5 email formats with first.last (ex. John.Smith@beigene.com) being used 89% of the time
BeiGene Email Formats | Percentage | |
---|---|---|
first.last | John.Smith@beigene.com | 89% |
first + last | JohnSmith@beigene.com | |
first_last | John_Smith@beigene.com | |
first | John@beigene.com | |
last | Smith@beigene.com |
Get Verified Emails
BeiGene financials insights
Gather financial insights about BeiGene, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
BeiGene Employee Growth Rate
Percentage of growth
1st year Mask
2nd year Mask
BeiGene Tech Stack
A closer look at the technologies used by BeiGene
Most Recent Scoops
BeiGene News & Media
BeiGene Announces Appointment of Giancarlo Benelli as Head of Europe
BASEL, Switzerland--(BUSINESS WIRE)--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the appointment of Giancarlo Benelli as Senior Vice President and Head of Europe, effective January 1st. This appointment will enhance the Company’s commitment to bring impactful medicines to more patients across Europe. “We are pleased to welcome Giancarlo to BeiGene in what continues to be a transformativTEVIMBRA Approved in U.S. for First-line Treatment of Gastric and Gastroesophageal Junction Cancers in Combination with Chemotherapy
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the U.S. Food and Drug Administration (FDA) has approved TEVIMBRA® (tislelizumab-jsgr), in combination with platinum and fluoropyrimidine-based chemotherapy, for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinoma (G/GEJ)BeiGene to Change Nasdaq Ticker Symbol to “ONC” on January 2; Present at 43rd Annual J.P. Morgan Healthcare Conference
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., announced it will change its Nasdaq ticker symbol to “ONC” on January 2, 2025, reflecting its long-standing commitment to delivering innovative oncology medicines globally. “As we enter our 15th year, changing our ticker to ONC reflects our unwavering commitment to leadership in oncology and mission to deBeiGene Announces Global Licensing Agreement for MAT2A Inhibitor
SAN MATEO, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: BGNE; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced it has entered into a global licensing agreement with CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (“CSPC”) for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. SYH2039 targets solid tumors that have a mutation called
Top Companies in United States
Top 10 companies in United States by revenue
Top 10 companies in United States by number of employees
Top 10 companies in United States by total funding amount
Frequently Asked Questions Regarding BeiGene
Founded in 2010 with administrative offices in Beijing, China; Cambridge, U.S.; and Basel, Switzerland., China, BeiGene is a global, science-driven biotechnology company, expediting development of a diverse pipeline of novel therapeutics.... Read More